Monitoring hub
503A Compounding Pharmacy Guide
Patient-specific prescriptions; state oversight; federal conditions; copies; bulk substances; limitations.
Section 503A and section 503B describe two different legal categories of compounder with different obligations, oversight, and permitted activities. A 503A compounder is a state-licensed pharmacy or a licensed physician. It may compound only against a valid prescription for an identified individual patient. It is exempt from FDA approval, CGMP, and adequate-directions-for-use requirements when the 503A conditions are met.
Key findings
- A 503A compounder is a state-licensed pharmacy or a licensed physician. It may compound only against a valid prescription for an identified individual patient. It is exempt from FDA approval
- A 503B outsourcing facility registers with FDA, may compound without patient-specific prescriptions, and may distribute for office use. It is exempt from FDA approval and adequate directions
- Registration is elective. A compounder is not required to become a 503B, and most do not. Absence from the federal register is therefore normal rather than a deficiency.
- Both categories are restricted from compounding a drug that is essentially a copy of a commercially available approved product, though the tests differ between the sections.
- Entity-specific compliance with this standard is not asserted on this page.
| Patient-specific prescriptions | Verification Pending |
|---|---|
| State oversight | Verification Pending |
| Federal conditions | Verification Pending |
| Copies | Verification Pending |
| Bulk substances | Verification Pending |
| Limitations. | Verification Pending |
| Federal framework | License Verified FDA sources verified 2026-07-23 |
| Entity-specific data | Verification Pending |
What this standard actually requires
Section 503A and section 503B describe two different legal categories of compounder with different obligations, oversight, and permitted activities.
A 503A compounder is a state-licensed pharmacy or a licensed physician. It may compound only against a valid prescription for an identified individual patient. It is exempt from FDA approval, CGMP, and adequate-directions-for-use requirements when the 503A conditions are met.
A 503B outsourcing facility registers with FDA, may compound without patient-specific prescriptions, and may distribute for office use. It is exempt from FDA approval and adequate directions for use, but NOT from CGMP.
Registration is elective. A compounder is not required to become a 503B, and most do not. Absence from the federal register is therefore normal rather than a deficiency.
Both categories are restricted from compounding a drug that is essentially a copy of a commercially available approved product, though the tests differ between the sections.
What is established about patient-specific prescriptions?
For 503A compounding pharmacy, patient-specific prescriptions is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where patient-specific prescriptions has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about state oversight?
For 503A compounding pharmacy, state oversight is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where state oversight has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about federal conditions?
For 503A compounding pharmacy, federal conditions is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where federal conditions has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about copies?
For 503A compounding pharmacy, copies is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where copies has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about bulk substances?
For 503A compounding pharmacy, bulk substances is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where bulk substances has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What does this page establish?
It establishes the framework and the source map for 503A compounding pharmacy, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.
What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.
What this means
- The framework governing 503A compounding pharmacy is cited to FDA primary sources.
- The record holding each element of patient-specific prescriptions is named.
- Verification dates are published on every field so staleness is visible.
What this does not mean
- That any entity connected with 503A compounding pharmacy is compliant or non-compliant.
- That the absence of a record indicates the absence of an issue.
- That this platform certifies or endorses any facility or preparation.
Status terms on this page follow the platform's published status vocabulary.
- No entity-specific record relating to 503A compounding pharmacy has been verified at this snapshot.
- Patient-specific prescriptions may change without notice to this platform.
- Regulatory positions change through rulemaking, guidance, and enforcement action.
- Records held by different agencies may disagree; conflicts are published as conflicts.
Sources verified for this page — 10 sources
- FDA — Information for Outsourcing Facilitieschecked 2026-07-23
- FDA — Q&A: Outsourcing Facility Registrationchecked 2026-07-23
- FDA — Registered Outsourcing Facilitieschecked 2026-07-23
- FDA — Aligning Federal and State Regulation of Compounderschecked 2026-07-23
- FDA — Outsourcing Facility Feeschecked 2026-07-23
- FDA — Compounded Drug Products That Are Essentially Copieschecked 2026-07-23
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)checked 2026-07-23
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)checked 2026-07-23
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)checked 2026-07-23
- FDA — Outsourcing Facility Fees guidancechecked 2026-07-23
Why 503A compounding pharmacy is hard to verify
Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.
First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.
That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.
| Structural feature | Consequence for verification | How this platform handles it |
|---|---|---|
| Split federal and state authority | No single register is complete for any entity | Both systems are named per field, and neither is presented as sufficient |
| Registration precedes inspection | A registration is not evidence of oversight | Registration and inspection are reported as separate facts |
| Records go stale silently | A citation without a date implies currency it may not have | Every field carries its own verification date |
| Observations are not findings | A Form 483 is frequently reported as a violation | Observations and final actions are stored and displayed separately |
| Resolved actions persist online | Closed matters get reported as current | Current and historical status are distinct states, never merged |
How does a 503A pharmacy actually differ in practice?
The statutory difference is one sentence: a 503A compounder may only dispense against a valid prescription for an identified individual patient. Everything else follows from that, and the practical consequences are larger than the sentence suggests.
It means a 503A pharmacy cannot hold finished stock of a compounded preparation waiting for orders. Each unit is made for a named person, which limits batch size, limits economies of scale, and makes the prescription itself part of the regulatory record.
It also means the oversight is state, not federal. A 503A pharmacy is inspected by its state board on the board's schedule, against standards the board adopts — most commonly USP chapters. FDA can inspect for cause but does not run a routine programme, and a 503A pharmacy appears on no federal facility register.
What does that mean for someone trying to verify one?
The record you need is held by a state board, and there are 51 of them with different registers, different search interfaces and different retention policies for disciplinary orders. There is no national lookup.
It also means the absence of a pharmacy from FDA's outsourcing facility register carries no negative signal whatsoever. The overwhelming majority of compounding pharmacies in the United States are 503A and will never appear there. Reading that absence as a red flag is the single most common error in consumer coverage of this sector.
What does carry signal: whether the pharmacy will name itself before you pay, whether its licence is current in the state where it operates and in yours, and whether it holds the specific permission class for sterile compounding if the preparation is an injection.
What this currently costs
Price is one of the few variables a reader can act on directly, so it is reported here rather than left to a separate page. Among the programmes this platform has verified by recomputation, the lowest regular injection rate is $145 per month on the longest commitment tier (NexLife), against higher rates on shorter terms.
Every tier behind that figure was recomputed from the published total rather than taken from the advertised per-month rate — 16 of 18 reconcile exactly, and the two that do not are published with the corrected figure on the regular injection affordability page.
Related records in this section
Section hub: Monitoring hubs · Methodology · Status definitions · Right to respond
Frequently asked questions
What does this page cover on 503A compounding pharmacy?
Patient-specific prescriptions; state oversight; federal conditions; copies; bulk substances; limitations.
What is established about patient-specific prescriptions?
Patient-specific prescriptions is tracked as part of 503A compounding pharmacy. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about state oversight?
state oversight is tracked as part of 503A compounding pharmacy. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about federal conditions?
federal conditions is tracked as part of 503A compounding pharmacy. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
How often is 503A compounding pharmacy rechecked?
FDA updates its registered outsourcing facility list weekly. Records on this platform carry their own check date so staleness is visible rather than hidden.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
- FDA — Aligning Federal and State Regulation of Compounders
- FDA — Outsourcing Facility Fees
- FDA — Compounded Drug Products That Are Essentially Copies
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
- FDA — Outsourcing Facility Fees guidance
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.